DBV Technologies S.A. (FRA:DBV)
2.335
-0.040 (-1.68%)
Last updated: Nov 24, 2025, 8:15 AM CET
DBV Technologies Revenue
Revenue (ttm)
$4.69M
Revenue Growth
-56.04%
P/S Ratio
88.12
Revenue / Employee
$42.63K
Employees
110
Market Cap
413.24M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 500.37K | 9.51% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.65% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.69K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
DBV Technologies News
- 19 days ago - DBVT Completes Key Phase 3 Trial for Peanut Allergy Treatment - GuruFocus
- 19 days ago - DBV Technologies On Track To Report Data From VITESSE Phase 3 Trial Of VIASKIN Peanut Patch In Q4 - Nasdaq
- 20 days ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years - Wallstreet:Online
- 20 days ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 27 days ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 4 weeks ago - DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - Wallstreet:Online